HPPD (Hallucinogen Persisting Perception Disorder): Causes, Symptoms & Treatment

Hallucinogen persisting perception disorder (HPPD) is a DSM-5-TR-recognized condition in which perceptual disturbances originally caused by hallucinogenic drugs persist or spontaneously recur days, months, or years after the triggering substance has fully cleared the body.

Unlike the brief recollective flashbacks most people associate with psychedelic use, HPPD involves genuine neurological changes in visual and perceptual processing that can profoundly impair daily functioning.

Understanding what causes HPPD, how it is diagnosed, and what treatment evidence exists determines whether recovery is possible.

Key Takeaways

• HPPD is a formal diagnostic category in DSM-5-TR (code 292.89 / F16.983), and according to the DSM-5, approximately 4.2% of people with a history of hallucinogen use experience distressing HPPD-like symptoms, though milder perceptual changes are substantially more common.
• LSD (lysergic acid diethylamide) is the hallucinogen most frequently associated with HPPD, but the condition has been documented following psilocybin, MDMA, ketamine, DMT, mescaline, and cannabis in susceptible individuals.
• Two clinically distinct subtypes exist: HPPD Type I (intermittent flashbacks that are mild, brief, and often self-limiting) and HPPD Type II (persistent, continuous perceptual disturbances that do not remit and cause significant occupational and social impairment).
• No FDA-approved pharmacological treatment for HPPD exists. The strongest evidence base involves clonazepam, lamotrigine, and risperidone, used off-label within a multimodal treatment framework that addresses both perceptual symptoms and co-occurring anxiety, depression, and substance use.
• The most reliable way to prevent HPPD progression is complete abstinence from all hallucinogens and cannabis, as both can trigger symptom exacerbation even in individuals with Type I presentations.

What Is HPPD?

HPPD is a documented neurological condition in which the visual and perceptual processing systems of the brain continue generating hallucinogen-like experiences after the drug has left the body, without any current drug use triggering the episode.

DSM-5-TR Diagnostic Criteria

• Criterion A (Perceptual recurrence): Following cessation of hallucinogen use, the re-experiencing of one or more perceptual symptoms that occurred during intoxication with the hallucinogen. DSM-5 specifically names geometric hallucinations, false perceptions of movement in peripheral visual fields, flashes of color, intensified colors, trails of moving objects (palinopsia), positive afterimages, halos around objects, macropsia, and micropsia as qualifying symptoms.
• Criterion B (Clinically significant distress or impairment): Symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
• Criterion C (Not attributable to another condition): The disturbance is not due to another medical condition (e.g., anatomical lesions, infections, or epilepsy), and is not better explained by another mental disorder such as delirium, major neurocognitive disorder, schizophrenia, or panic disorder with visual symptoms.
• Reality testing is maintained: A critical distinguishing feature of HPPD is that affected individuals retain awareness that their perceptions are anomalous. Unlike active psychosis, persons with HPPD typically know the visual disturbances are not real, which is the primary reason the condition is classified separately from schizophrenia spectrum disorders.

HPPD Type I vs. Type II

• HPPD Type I (flashback subtype): Characterized by brief, intermittent episodes of perceptual re-experiencing that are typically triggered by specific stimuli such as stress, sleep deprivation, or cannabis use. Most episodes last seconds to minutes. Type I often has a self-limiting course and does not necessarily require pharmacological intervention. While this subtype is not separately coded in the current DSM-5, it corresponds to ICD-10 diagnostic category F16.7.
• HPPD Type II (persistent subtype): Characterized by continuous, non-episodic perceptual disturbances that are always present and do not remit. Visual snow, geometric patterns, afterimages, and altered color perception are constantly active features of the visual field. Type II matches the DSM-5-TR criteria most closely and is the subtype associated with significant long-term impairment and the most urgent treatment need.

What Causes HPPD?

HPPD causes remain incompletely understood, but converging evidence from clinical neuroscience identifies serotonergic dysregulation, cortical disinhibition, and specific neuroplastic changes in visual cortex circuits as the primary mechanistic drivers.

Neurobiological Causes

• Serotonin 2A receptor (5-HT2A) disruption: Hallucinogens produce their primary perceptual effects by agonizing 5-HT2A receptors in the visual cortex, particularly in layer V pyramidal neurons of the primary visual cortex (V1). Henry Abraham, MD, who first systematically characterized HPPD in 1983, proposed that repeated 5-HT2A stimulation may produce lasting changes in receptor sensitivity, leading visual circuits to generate spontaneous perceptual activity in the absence of external stimulation.
• Loss of inhibitory interneuron function (cortical disinhibition): The leading mechanistic hypothesis for HPPD Type II is that LSD and other serotonergic hallucinogens reduce the activity of inhibitory GABAergic interneurons in the visual cortex. These interneurons normally suppress background neural noise in visual processing circuits. When their function is reduced, spontaneous firing in excitatory visual neurons creates the persistent visual disturbances characteristic of persistent HPPD. This cortical disinhibition model was supported by Halpern and Pope in their 2003 review of HPPD prevalence and etiology in clinical populations.
• Palinopsia as a neural signature: Trailing afterimages (palinopsia) are among the most diagnostically specific features of HPPD and represent a direct measure of impaired motion-detection processing in the dorsal visual stream. Palinopsia in HPPD reflects disruption of the magnocellular visual pathway, which normally suppresses persistence of moving objects in the visual field after they pass.
• Visual snow syndrome overlap: Visual snow, the perception of a constant static overlay across the entire visual field, is one of the most common features of HPPD Type II and is now recognized as a distinct neurological entity overlapping significantly with HPPD. Neuroimaging studies demonstrate hypermetabolism in the lingual gyrus and cuneus, regions of the visual cortex involved in color and pattern processing, suggesting a permanent alteration in visual cortex baseline excitability.

Genetic and Individual Vulnerability Factors

• Pre-existing anxiety and dissociation sensitivity: Individuals with high baseline anxiety sensitivity, dissociative tendencies, or a personal or family history of anxiety disorders appear to be at elevated risk for HPPD following hallucinogen exposure. The mechanism is thought to involve heightened 5-HT2A receptor sensitivity at baseline, producing stronger initial hallucinogen effects and greater vulnerability to lasting receptor changes.
• Polydrug exposure: Research consistently identifies cannabis use as a significant HPPD trigger and exacerbating factor in individuals with established HPPD. THC’s modulation of endocannabinoid circuits that intersect with serotonergic and GABAergic visual cortex pathways appears to reinitiate or worsen perceptual symptoms even in individuals who have abstained from hallucinogens for extended periods.

Substance-Related and Triggering Causes

• LSD (lysergic acid diethylamide): The most frequently reported HPPD-triggering substance, with dose-response evidence suggesting that multiple high-dose LSD exposures increase risk substantially relative to single low-dose use. However, HPPD has been documented following a single LSD use in susceptible individuals.
• Psilocybin (magic mushrooms): The second most commonly reported trigger. The growing clinical use of psilocybin in therapeutic settings has generated new case reports of HPPD in research participants, highlighting that HPPD risk is not limited to recreational poly-drug contexts.
• MDMA (3,4-methylenedioxymethamphetamine): MDMA’s combined serotonergic, dopaminergic, and noradrenergic actions produce HPPD through a partially different mechanism than classical psychedelics, potentially involving serotonin transporter downregulation that alters baseline visual cortex arousal.
• Contaminants in the illicit drug supply: The increasing contamination of street drugs with fentanyl and other adulterants means individuals who believe they are using psilocybin or MDMA may instead be consuming chemically dissimilar substances with different neurological risk profiles. Fentanyl contamination in counterfeit pills sold as psychedelics is now documented.

Developmental and Environmental Causes

• Early-onset use: Use of hallucinogens during adolescence, when visual cortex development is ongoing and 5-HT2A receptor distribution is still maturing, is associated with greater HPPD risk than adult-onset exposure.
• High-dose or frequent use: Polydrug use patterns involving frequent, high-dose hallucinogen exposure substantially elevate HPPD risk relative to infrequent, low-dose use, consistent with a dose-dependent effect on GABAergic interneuron function.

HPPD Symptoms: What You May Be Experiencing

HPPD symptoms span visual, cognitive, and emotional domains, with visual disturbances being the defining and most distressing feature for most affected individuals.

Core Visual Symptoms

• Visual snow: A persistent, continuous overlay of small, flickering dots across the entire visual field, resembling television static. Present in Type II HPPD as a constant background feature independent of other visual disturbances.
• Trailing and afterimages (palinopsia): Moving objects leave visual traces or trails behind their path of motion. Stationary objects produce persistent afterimages that outlast normal retinal processing. These palinoptic phenomena are among the most diagnostically reliable HPPD markers.
• Geometric hallucinations and patterns: Spontaneous appearance of lattice patterns, spirals, honeycombs, and geometric grids overlaid on the visual field, particularly prominent in peripheral vision and in low-lighting conditions.
• Altered perception of size and shape: Objects may appear abnormally large (macropsia), abnormally small (micropsia), or geometrically distorted (metamorphopsia). These perceptual distortions can make familiar environments feel profoundly disorienting.
• Halos and auras: Bright halos surrounding light sources and objects, and color auras visible around people or objects in the visual periphery.

Cognitive and Emotional Symptoms

• Depersonalization and derealization: A sense of detachment from oneself (depersonalization) or from the surrounding environment (derealization) commonly accompanies HPPD perceptual disturbances. Individuals describe feeling as if they are observing themselves from outside their body or as if the world lacks three-dimensional solidity.
• Anxiety and panic: The unpredictability and loss of control over visual perception produces significant anxiety in most HPPD patients. For some individuals, the visual disturbances trigger full panic attacks, particularly in public environments where perceptual destabilization is frightening and difficult to manage.
• Depression: Chronic perceptual disturbance that impairs occupational function, driving ability, reading, and social interaction inevitably produces secondary depression. The perceived permanence of symptoms, “will this ever go away,” is a primary driver of hopelessness in the HPPD population.

Long-Term Effects Without Treatment

• Occupational and social impairment: HPPD Type II can prevent safe operation of motor vehicles, cause visual difficulty with reading and screen work, and create profound social anxiety from the unpredictability of symptoms in public settings.
• Secondary substance use disorders: A significant proportion of HPPD-affected individuals develop secondary alcohol or benzodiazepine use disorders as they attempt to self-medicate the anxiety and perceptual disturbances, creating compounding clinical complexity that requires integrated dual diagnosis treatment.
• Suicidal ideation: In severe, persistent cases, HPPD-related hopelessness and functional impairment generates significant suicidal ideation risk that must be assessed and monitored in all clinical presentations.

Is HPPD Brain Damage?

HPPD is not classified as brain damage in the conventional structural sense, as standard MRI and CT imaging generally do not reveal gross anatomical abnormalities in HPPD patients. However, functional neuroimaging studies using PET and fMRI have documented measurable abnormalities in visual cortex metabolic activity in HPPD Type II, confirming that the condition reflects genuine neurophysiological changes rather than purely psychological phenomena.

The most accurate clinical characterization of HPPD is that it represents a pathological alteration in visual cortex excitability and inhibitory circuit function, analogous to the neurophysiological changes seen in other cortical excitability disorders such as migraine with aura or cortical spreading depression. These changes are neurobiologically real, clinically meaningful, and not simply a matter of psychological suggestion or anxiety-driven misinterpretation of normal perceptual variability.

HPPD vs. Other Conditions: How to Tell the Difference

Accurate differential diagnosis is essential for HPPD, as the visual and psychiatric features overlap significantly with several other conditions requiring different treatment approaches entirely.

HPPD is distinguished from schizophrenia primarily by temporal context and reality testing. Schizophrenia spectrum disorders produce hallucinations accompanied by delusional thinking and impaired insight; the individual cannot reliably distinguish the hallucination from reality. HPPD individuals retain full awareness that their perceptions are anomalous, and symptoms are temporally linked to prior hallucinogen use. A structured clinical interview establishing the timeline of drug use alongside symptom onset, combined with neuropsychological testing and urine toxicology, is the primary diagnostic tool.

Migraine with aura produces visual disturbances including scintillating scotomas (flickering arc-shaped patterns), photophobia, and geometric visual phenomena that closely resemble HPPD symptoms. The distinguishing features are headache accompaniment, the typically shorter duration of migraine aura (20 to 60 minutes), and the absence of a triggering hallucinogen history. A detailed headache history and neurological examination differentiate the conditions in the majority of cases.

Anxiety disorder with depersonalization-derealization features produces derealization episodes that superficially resemble HPPD. The distinguishing feature is that anxiety-driven derealization does not produce the specific visual phenomena of HPPD, including visual snow, palinopsia, and geometric hallucinations. Thorough assessment of visual symptom phenomenology is the key diagnostic step.

Treatment for HPPD

HPPD treatment is multimodal, combining pharmacological symptom management, psychotherapy for co-occurring psychiatric conditions, and structured lifestyle modifications with the highest evidence-based priority being complete abstinence from all hallucinogens and cannabis.

First-Line Pharmacological Treatments

• Clonazepam (Klonopin): The benzodiazepine clonazepam has the most consistent clinical evidence for HPPD symptom reduction among all off-label pharmacological options. It acts by enhancing GABAergic inhibitory transmission, directly addressing the cortical disinhibition mechanism implicated in HPPD Type II. Clonazepam reduces visual snow intensity, trailing, and anxiety in a significant proportion of patients. Use must be carefully monitored given the inherent risk of benzodiazepine dependence in a population that may already have substance use history; however, a comprehensive benzodiazepine treatment referral pathway is important context for clinicians prescribing in this population.
• Lamotrigine (Lamictal): An anticonvulsant that inhibits voltage-gated sodium channels and reduces glutamate release. Lamotrigine targets the cortical excitability imbalance in HPPD by stabilizing neuronal firing in visual cortex circuits. Several case reports and a small open-label study demonstrate visual symptom improvement with lamotrigine monotherapy. Its favorable side-effect profile relative to antipsychotics makes it a preferred first-line trial in Type II HPPD.
• Naltrexone: The opioid receptor antagonist naltrexone has documented case-level evidence in reducing HPPD perceptual symptoms. The proposed mechanism involves modulation of opioid-mediated regulation of serotonergic and dopaminergic circuits that interface with visual cortex excitability. Currently off-label; selected as a second-line trial in HPPD cases where lamotrigine and clonazepam have shown insufficient response.

First-Line Behavioral and Psychotherapy Approaches

• Cognitive Behavioral Therapy (CBT): CBT is the primary evidence-based psychotherapy for HPPD-associated anxiety, panic, and depression. CBT techniques targeting catastrophic interpretation of visual symptoms, anxiety sensitivity reduction, and behavioral activation to address depression directly address the psychological impairment that amplifies HPPD distress. The reduction in anxiety that CBT produces often secondarily reduces HPPD symptom intensity, as sympathetic nervous system arousal appears to worsen perceptual symptom severity.
• Mindfulness-Based Stress Reduction (MBSR): MBSR teaches individuals to relate to perceptual disturbances as observable neurological events rather than catastrophic threats. By reducing the distress response to visual symptoms, mindfulness practice substantially reduces HPPD-related functional impairment even when the perceptual phenomena themselves do not fully resolve.
• Acceptance and Commitment Therapy (ACT): ACT’s emphasis on accepting rather than eliminating internal experiences, and committing to value-driven behavior despite their presence, is particularly well-suited to HPPD Type II presentations where complete symptom resolution may not be achievable. ACT prevents the avoidance and self-isolation patterns that extend impairment beyond the symptoms themselves.

Second-Line and Adjunct Treatments

• Risperidone (with caution): The atypical antipsychotic risperidone has been used in HPPD but carries a documented risk of symptom worsening in some patients. Risperidone’s 5-HT2A antagonism theoretically should reduce visual cortex excitability, but case reports of paradoxical symptom exacerbation limit its utility. It is considered a carefully monitored second-line option when lamotrigine and clonazepam are insufficient.
• Clonidine (Catapres): The alpha-2 adrenergic agonist clonidine, which suppresses noradrenergic output from the locus coeruleus, has shown symptom reduction in HPPD case reports by reducing the generalized arousal that exacerbates cortical excitability. Particularly useful when co-occurring anxiety and autonomic hyperreactivity are prominent.

Emerging and Investigational Treatments

• Repetitive Transcranial Magnetic Stimulation (rTMS): rTMS targeting visual cortex excitability has been proposed as a treatment for HPPD based on its known efficacy in modulating cortical firing patterns in epilepsy and depression. Limited case-level evidence is available; active investigation is ongoing but no clinical trial data is yet sufficient for guideline-level recommendation.
• Neurofeedback: EEG-based neurofeedback training targeted at visual cortex alpha-wave patterns is under preliminary investigation for HPPD, with the theoretical goal of training the brain to generate normal inhibitory activity in visual circuits without pharmacological intervention. Currently investigational only.

Does HPPD Go Away?

The prognosis for HPPD depends substantially on subtype and whether complete abstinence is maintained. HPPD Type I, characterized by intermittent flashbacks, has a favorable self-limiting course in the majority of cases. Complete abstinence from hallucinogens and cannabis, combined with anxiety management, allows Type I symptoms to diminish significantly or resolve entirely within weeks to months in most patients.

HPPD Type II, with persistent, continuous perceptual disturbances, carries a more variable prognosis. A proportion of Type II patients experience significant improvement with pharmacological treatment and sustained abstinence. A smaller proportion experience permanent or indefinitely persistent visual symptoms that are managed rather than cured. Early treatment initiation, complete substance abstinence, and integrated dual diagnosis care for co-occurring anxiety and depression are the strongest predictors of positive outcomes in Type II HPPD.

Treatment at New Spirit Recovery

New Spirit Recovery addresses HPPD within its integrated dual diagnosis treatment framework, recognizing that HPPD in clinical populations almost invariably co-occurs with substance use disorders, anxiety disorders, or depressive disorders that require simultaneous treatment.

Dual Diagnosis and Mental Health Treatment

• Integrated psychiatric evaluation: New Spirit Recovery’s dual diagnosis program provides comprehensive psychiatric evaluation within 24 to 72 hours of admission. For individuals presenting with HPPD alongside substance use disorders, the Nurse Practitioner and Medical Director assess and manage perceptual symptom severity, co-occurring anxiety and depression, and substance withdrawal simultaneously. The integrated treatment model ensures that hallucinogen cessation is medically supervised and that the HPPD component does not go unaddressed during the addiction treatment episode.

Residential Treatment

• Structured environment for perceptual stabilization: New Spirit Recovery’s residential treatment program provides a highly structured, low-stimulation clinical environment that reduces the sensory triggers that commonly exacerbate HPPD symptoms, including stress, sleep disruption, and substance use. Six hours of daily clinical programming integrating CBT, DBT, EMDR, ACT, and mindfulness-based modalities addresses both the substance use disorder and the anxiety and depressive components of HPPD impairment within a single therapeutic framework.

Medical Detox

• Safe withdrawal from polysubstance use: Individuals with HPPD who also have alcohol, cannabis, or benzodiazepine use disorders require medically supervised withdrawal management before HPPD-specific treatment can be optimally delivered. New Spirit Recovery’s medical detox program provides 24-hour physician oversight, continuous nursing coverage, and medication-assisted withdrawal management to ensure safe and supported detoxification as the clinical foundation for HPPD treatment.

Rewired Curriculum

• Emotional regulation for HPPD-related distress: The proprietary Rewired curriculum developed by co-founder Erica Spiegelman delivers 10 modules addressing emotional regulation, self-awareness, and healthy coping. For individuals with HPPD, the distress tolerance and mindfulness components of the curriculum directly support the psychological stabilization that is essential for managing perceptual symptoms and preventing the secondary substance use disorders that HPPD anxiety often generates.

Medication-Assisted Treatment

• Adjunct pharmacological support: New Spirit Recovery’s medication-assisted treatment program provides non-addictive pharmacological support including non-benzodiazepine anti-anxiety medications, mood stabilizers, and psychiatric medications for co-occurring conditions. All medication decisions involve the Medical Director, Nurse Practitioner, therapists, and client in collaborative planning appropriate to the individual’s full clinical presentation, including HPPD symptom management needs.

Frequently Asked Questions

What are the symptoms of HPPD?

HPPD symptoms are primarily visual and include visual snow (persistent static overlay), trailing afterimages (palinopsia), geometric patterns and lattices in the visual field, halos around objects and light sources, altered size perception (macropsia, micropsia), and intensified colors. Non-visual symptoms include depersonalization, derealization, anxiety, and panic. Reality testing is maintained; most individuals with HPPD are aware their perceptions are anomalous.

Does HPPD go away eventually?

HPPD Type I (intermittent flashbacks) is often self-limiting and resolves significantly with abstinence from hallucinogens and cannabis, combined with anxiety management, within weeks to months for most individuals. HPPD Type II (persistent visual disturbances) has a more variable course. A proportion of Type II patients achieve substantial improvement with pharmacological treatment and sustained abstinence; a smaller proportion experience long-term persistent symptoms managed rather than fully resolved. Early treatment initiation substantially improves prognosis in both subtypes.

Is HPPD brain damage?

HPPD is not structural brain damage as detected by conventional MRI or CT imaging. It represents measurable neurophysiological changes in visual cortex excitability and inhibitory circuit function, confirmed by functional neuroimaging in research studies. These changes are real and clinically meaningful but are better characterized as a cortical excitability disorder than as structural brain injury, a distinction that has important implications for prognosis and treatment response.

How rare is HPPD?

The DSM-5 estimates that approximately 4.2% of hallucinogen users experience distressing HPPD-like symptoms. Milder perceptual aftereffects without significant functional impairment are substantially more common. Because HPPD is both underrecognized and underreported, true prevalence may differ from existing estimates. Halpern and Pope estimated in their 2003 systematic review that symptoms occur in fewer than 5% of individuals treated with LSD in clinical settings but in up to 50% of polydrug users, highlighting how strongly polysubstance use amplifies risk.

What drugs cause HPPD?

LSD is the most frequently documented HPPD trigger. Psilocybin, MDMA, ketamine, mescaline, DMT, dextromethorphan, synthetic cannabinoids, and cannabis have all been associated with HPPD in case reports and clinical series. Cannabis does not typically trigger de-novo HPPD but consistently exacerbates existing HPPD symptoms and can induce flashbacks in Type I cases. Fentanyl contamination of the illicit psychedelic supply means some HPPD presentations may involve neurological effects from adulterants rather than the intended hallucinogen alone.

Can HPPD be treated effectively?

Yes, though no FDA-approved treatment exists. The strongest clinical evidence supports clonazepam and lamotrigine for symptom reduction, CBT for HPPD-associated anxiety and depression, and mindfulness-based approaches for distress management. Complete abstinence from all hallucinogens and cannabis is the single most important intervention and significantly improves prognosis independent of pharmacological treatment. Early treatment initiation, integrated dual diagnosis care, and sustained abstinence produce the best long-term outcomes for both HPPD subtypes.

Is HPPD the same as psychosis?

No. The defining difference is reality testing. HPPD individuals retain full awareness that their perceptions are anomalous and do not originate from external reality. Psychosis produces hallucinations or delusions that the individual cannot reliably distinguish from reality. HPPD does not impair the fundamental capacity for reality testing. Clinical differential diagnosis using structured psychiatric interview and temporal history of substance use alongside symptom onset is the most reliable way to distinguish HPPD from schizophrenia spectrum disorders.

References

1. American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Publishing.
2. Halpern, J. H., & Pope, H. G. (2003). Hallucinogen persisting perception disorder: What do we know after 50 years? Drug and Alcohol Dependence, 69(2), 109–119.
3. Abraham, H. D. (1983). Visual phenomenology of the LSD flashback. Archives of General Psychiatry, 40(8), 884–889.
4. Vis, R., Mol, M., Koerselman, F., & Bruijnzeel-Koomen, C. A. F. M. (2021). On perception and consciousness in HPPD: A systematic review. Frontiers in Neuroscience, 15, 675768.